230 related articles for article (PubMed ID: 7523310)
21. N-myc oncogene and stage IV-S neuroblastoma. Preliminary observations on ten cases.
Nakagawara A; Sasazuki T; Akiyama H; Kawakami K; Kuwano A; Yokoyama T; Kume K
Cancer; 1990 May; 65(9):1960-7. PubMed ID: 2196987
[TBL] [Abstract][Full Text] [Related]
22. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma.
Svensson T; Rydén M; Schilling FH; Dominici C; Sehgal R; Ibáñez CF; Kogner P
Eur J Cancer; 1997 Oct; 33(12):2058-63. PubMed ID: 9580079
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas.
Hamano S; Ohira M; Isogai E; Nakada K; Nakagawara A
Int J Oncol; 2004 Jun; 24(6):1457-66. PubMed ID: 15138588
[TBL] [Abstract][Full Text] [Related]
24. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
25. Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview.
Tsuchida Y; Hemmi H; Inoue A; Obana K; Yang HW; Hayashi Y; Kanda N; Shimatake H
Tumour Biol; 1996; 17(2):65-74. PubMed ID: 8658015
[TBL] [Abstract][Full Text] [Related]
26. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
27. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors.
Kogner P; Barbany G; Björk O; Castello MA; Donfrancesco A; Falkmer UG; Hedborg F; Kouvidou H; Persson H; Raschella G
Prog Clin Biol Res; 1994; 385():137-45. PubMed ID: 7972205
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas.
Combaret V; Gross N; Lasset C; Frappaz D; Peruisseau G; Philip T; Beck D; Favrot MC
J Clin Oncol; 1996 Jan; 14(1):25-34. PubMed ID: 8558206
[TBL] [Abstract][Full Text] [Related]
29. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
30. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis.
Rydén M; Sehgal R; Dominici C; Schilling FH; Ibáñez CF; Kogner P
Br J Cancer; 1996 Sep; 74(5):773-9. PubMed ID: 8795581
[TBL] [Abstract][Full Text] [Related]
31. Amplification of N-myc oncogene in stage II and IVS neuroblastomas may be a prognostic indicator.
Nakagawara A; Ikeda K; Tsuda T; Higashi K; Okabe T
J Pediatr Surg; 1987 May; 22(5):415-8. PubMed ID: 3585663
[TBL] [Abstract][Full Text] [Related]
32. Amplification of N-myc as a prognostic marker for patients with neuroblastoma.
Schwab M
Semin Cancer Biol; 1993 Feb; 4(1):13-8. PubMed ID: 8448374
[TBL] [Abstract][Full Text] [Related]
33. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas.
Leone A; Seeger RC; Hong CM; Hu YY; Arboleda MJ; Brodeur GM; Stram D; Slamon DJ; Steeg PS
Oncogene; 1993 Apr; 8(4):855-65. PubMed ID: 8384356
[TBL] [Abstract][Full Text] [Related]
34. Neuroblastoma: inverse relationship between expression of N-myc and NGF-r.
Christiansen H; Christiansen NM; Wagner F; Altmannsberger M; Lampert F
Oncogene; 1990 Mar; 5(3):437-40. PubMed ID: 2156211
[TBL] [Abstract][Full Text] [Related]
35. Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas.
Tsuda T; Obara M; Hirano H; Gotoh S; Kubomura S; Higashi K; Kuroiwa A; Nakagawara A; Nagahara N; Shimizu K
Cancer; 1987 Aug; 60(4):820-6. PubMed ID: 3594401
[TBL] [Abstract][Full Text] [Related]
36. Detection of N-myc amplification in neuroblastomas using Southern blotting on fine needle aspirates.
Barroca H; Carvalho JL; da Costa MJ; Cirnes L; Seruca R; Schmitt FC
Acta Cytol; 2001; 45(2):169-72. PubMed ID: 11284301
[TBL] [Abstract][Full Text] [Related]
37. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
38. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis.
Kogner P; Barbany G; Dominici C; Castello MA; Raschellá G; Persson H
Cancer Res; 1993 May; 53(9):2044-50. PubMed ID: 8481906
[TBL] [Abstract][Full Text] [Related]
39. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
[TBL] [Abstract][Full Text] [Related]
40. Specific expression of the ret proto-oncogene in human neuroblastoma cell lines.
Ikeda I; Ishizaka Y; Tahira T; Suzuki T; Onda M; Sugimura T; Nagao M
Oncogene; 1990 Sep; 5(9):1291-6. PubMed ID: 2216455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
